An Open-Label, Multinational Study Of The Efficacy And Safety Of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs AVR 02 (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors AVROBIO
- 07 Mar 2018 Status changed from planning to recruiting.
- 07 Feb 2018 New trial record
- 01 Feb 2018 According to a AVROBIO media release, company plans to initiate the study in 2018.